Kelyrab 20 Tablet contains Rabeprazole 20 mg, a proton pump inhibitor (PPI) used primarily to reduce gastric acid secretion. It is indicated for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, Zollinger-Ellison syndrome, and other conditions involving excessive stomach acid production. Rabeprazole acts by selectively inhibiting the H+/K+ ATPase enzyme system located on the gastric parietal cells, thereby suppressing the final step of acid production in the stomach. This results in decreased acidity, promoting healing of acid-related damage and relief from symptoms such as heartburn and acid regurgitation. Kelyrab 20 is typically administered orally once daily, preferably before meals, and the dosage may be adjusted based on the severity of the condition and patient response. It is well tolerated, with common side effects including headache, diarrhea, nausea, and abdominal pain. Caution is advised in patients with liver impairment, and long-term use should be monitored due to potential risks such as vitamin B12 deficiency and increased susceptibility to gastrointestinal infections. Kelyrab 20 Tablet should be used under medical supervision to ensure appropriate diagnosis, dosing, and monitoring of therapeutic outcomes.